Oral lysophilisates containing pvp/va
AssigneeCephalon France
InventorThanh-Tam Nguyen
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel oral pharmaceutical compositions in lyophilized form, in which the dissolution and the bioavailability of the active ingredient that they contain are improved. The compositions according to the invention comprise in particular a polyvinyl acetate/polyvinylpyrrolidone copolymer. The oral lyophilisates according to the invention are particularly suitable for the production of medicaments based on active ingredients which have low solubility or very low solubility in water or which are virtually insoluble in water.
Claims16
A pharmaceutical composition in oral lyophilizate form, which is obtained by lyophilization of an aqueous liquid phase free of organic solvent and of ionic surfactant, containing at least one active ingredient which has low solubility or very low solubility or which is virtually insoluble in water, and one polyvinylpyrrolidone/polyvinyl acetate copolymer in a PVP/VA ratio of 60/40.
An oral lyophilizate comprising at least one polyvinylpyrrolidone/polyvinyl acetate copolymer, said polyvinylpyrrolidone and polyvinyl acetate being in a PVP/VA ratio equal to 60/40, and one active ingredient which has low solubility or very low solubility or which is virtually insoluble in water, wherein the active ingredient/(polyvinylpyrrolidone/polyvinyl acetate copolymer) ratio is between 1:20 and 5:1, provided that if the active ingredient is docetaxel and the copolymer is PVP-VA 64, the active ingredient/copolymer ratio does not equal to 300/2,700 (0.11).
A process for producing an oral lyophilizate comprising at least one active ingredient, comprising the steps of:
- a) preparation of a homogeneous aqueous microemulsion liquid phase free of ionic surfactant or of organic solvent, comprising said active ingredient(s) in solution, suspension or emulsion and a polyvinylpyrrolidone/polyvinyl acetate copolymer, said polyvinylpyrrolidone and polyvinyl acetate being in a PVP/VA ratio equal to 60/40, dissolved in this aqueous phase,
- b) sublimation of the water contained in the liquid phase and, optionally,
- c) additional drying of the resulting formulation.
Dependencies are inferred from the claim text.